Heterociclos de interés biológico y terapéutico
Hospital Universitario de la Princesa
Madrid, EspañaPublications en collaboration avec des chercheurs de Hospital Universitario de la Princesa (8)
2022
2020
-
Antioxidant, anti-inflammatory and neuroprotective profiles of novel 1,4-dihydropyridine derivatives for the treatment of alzheimer’s disease
Antioxidants, Vol. 9, Núm. 8, pp. 1-20
-
Aza-CGP37157-lipoic hybrids designed as novel Nrf2-inducers and antioxidants exert neuroprotection against oxidative stress and show neuroinflammation inhibitory properties
Drug Development Research, Vol. 81, Núm. 3, pp. 283-294
-
NRF2 Regulation Processes as a Source of Potential Drug Targets against Neurodegenerative Diseases
Biomolecules, Vol. 10, Núm. 6
2017
-
Discovery of the first dual GSK3β inhibitor/Nrf2 inducer. A new multitarget therapeutic strategy for Alzheimer's disease
Scientific Reports, Vol. 7
-
ITH14001, a CGP37157-Nimodipine Hybrid Designed to Regulate Calcium Homeostasis and Oxidative Stress, Exerts Neuroprotection in Cerebral Ischemia
ACS Chemical Neuroscience, Vol. 8, Núm. 1, pp. 67-81
2014
-
New 5-unsubstituted dihydropyridines with improved CaV1.3 selectivity as potential neuroprotective agents against ischemic injury
Journal of Medicinal Chemistry, Vol. 57, Núm. 10, pp. 4313-4323
2013
-
Identification of 4,6-diaryl-1,4-dihydropyridines as a new class of neuroprotective agents
MedChemComm, Vol. 4, Núm. 3, pp. 590-594